Investors

Share Information

Number of shares: 439 622 756

Total number of outstanding warrants: 683,980 (see below for details)

Warrant

Exercise price/share

Maximum amount of warrants

Expiry date

CBF1

EUR 1.26

12,629 shares

August 18, 2020

CBF2

EUR 0.74

21,513 shares

September 22, 2020

CBF3

EUR 0.50

34,231 shares

October 20, 2020

CBF4

EUR 0.45

74,384 shares

November 8, 2020

CBF5

EUR 0.43

148,769 shares

November 16, 2020

CBF6

EUR 0.41

334,462 shares

December 5, 2020

KREOS

EUR 0.41

57,992 shares

July 13, 2022

 


Stock option plans total: 39,330,040 (see below for details)

Option scheme

Subscription price/share

Maximum amount of option rights

Subscription period

2013A

EUR 0.30

1,721 shares

 1.12.2013-31.12.2020

2016B

EUR 0.23

94,191 shares

 1.7.2019-15.12.2024

2016C

EUR 0.30

121,513 shares

1.7.2020-15.12.2025**

2017

EUR 0.23

39,285 shares

 20.10.2018-31.3.2023

2018A

EUR 0.07

36,665 shares

1.7.2022-15.12.2027

2018B

EUR 0.01

36,665 shares

1.7.2023-15.12.2028
2020AEUR 0.0313,000,000 shares1.7.2022-15.12.2027
2020B*13,000,000 shares1.7.2023-15.12.2028
2020C**13,000,000 shares1.7.2024-15.12.2029

 

*The share subscription price for stock options 2020B is the trade volume weighted average quotation of the share on Nasdaq First North Growth Market Finland during twenty (20) trading days following the release date of the Company´s Financial Statements of the year 2020

**The share subscription price for stock options 2020C the trade volume weighted average quotation of the share on Nasdaq First North Growth Market Finland during twenty (20) trading days following the release date of the Company´s Financial Statements of the year 2021
                                    

Board of Directors authorizations outstanding total: 51 977 156 shares (see below extract from the EGM 2019 and AGM 2020 decisions)

AUTHORIZING THE BOARD OF DIRECTORS TO DECIDE ON THE ISSUANCE OF SHARES AS WELL AS THE ISSUANCE OF OPTION RIGHTS AND OTHER SPECIAL RIGHTS ENTITLING TO SHARES

In accordance with the proposal of the Board of Directors, the 11 November 2019 Extraordinary General Meeting of Shareholders resolved to authorize the Board of Directors to decide on issuances of new shares either against payment or without consideration as follows:

The authorization would be given to a maximum quantity of 10,000,000 new shares.
The new shares may be issued to the Company's shareholders in proportion to their current shareholdings in the Company or deviating from the shareholders' pre-emptive right through one or more directed share issue, if the Company has a weighty financial reason to do so, such as developing the Company's equity structure, minimize or reduce debts, implementing mergers and acquisitions or other restructuring measures aimed at developing the Company's business, financing of investments and operations or using the shares as a part of the Company's remuneration and compensation system. The Board of Directors shall decide upon terms and scope related to share issues.

Based and within the limits of this authorization, the Board of Directors can also decide on issuance(s) of option rights or other special rights set forth in Chapter 10 Section 1 of the Limited Liability Companies Act complementing or replacing issuance(s) of shares.

The subscription price of the new shares can be recorded partly or fully to the invested unrestricted equity reserve or to share capital according to the decision of the Board of Directors.

The Board of Directors is entitled to decide on conditions regarding the issuance of shares as well as the issuance of option rights or other special rights entitling to shares.

The authorization is be valid for one year from the Extraordinary General Meeting.

 

THE ANNUAL GENERAL MEETING OF SHAREHOLDERS AUTHORIZED THE BOARD OF DIRECTORS TO DECIDE ON SHARE ISSUES AS WELL AS ISSUES OF OPTION RIGHTS AND OTHER SPECIAL RIGHTS ENTITLING TO SHARES, PURSUANT TO CHAPTER 10 OF THE COMPANIES ACT, AS FOLLOWS:

The shares issued under the authorization are new or those in the Company's possession. Based and within the limits of this authorization, the Board of Directors can also decide on issuance(s) of option rights or other special rights set forth in Chapter 10 the Limited Liability Companies Act complementing or replacing issuance(s) of shares.

Under the authorization, a maximum of four hundred twenty million (420,000,000) shares may be issued, which corresponds to approximately 86.99 percent of all the shares in the Company after the share issue, provided that new shares are issued, considering all registered shares of the Company.

In issue of new ordinary shares, the shareholders have the right to subscribe for new shares in proportion to their existing holdings of the shares of the Company. The Board of Directors has the right to decide upon the offering to parties determined by the Board of Directors of any shares that may remain unsubscribed for pursuant to the shareholders' pre-emptive subscription right. In connection with any shares which remain unsubscribed in such subscription rights issue, the Board of Directors is authorized to resolve on directed share issues or directed issues of option rights or special rights entitling to shares in deviation from the shareholders' pre-emptive right, provided that there is a weighty financial reason for the Company to do so. The shares and option rights or other special rights entitling to shares can hence be issued in one or more tranches.

In the issuance of shares in the subscription rights issue, the Board of Directors proposes that the preliminary subscription price is EUR 0.006. Taking into account such price level, the major shareholders of the Company, Kaikarhenni Oy and Ossi Haapaniemi jointly with his related-party companies, have provided a preliminary commitment to the Company regarding subscription of new shares in such subscription rights issue based on their existing ownership of approximately 24% which would be equal to in aggregate approximately EUR 0.5 million based on such price level.

The Board of Directors is authorized to resolve on the final subscription price as well as all terms for the share issues and granting of the special rights entitling to shares.

The authorization does not invalidate prior resolved and registered authorizations made at the General Meeting of Shareholders regarding share issues and issuances of option rights and other special rights entitling to shares.

The authorization is valid for one (1) year from the decision of the Annual General Meeting of Shareholders.

The authorization may be used for the future financing needs of the Company, developing the equity structure, minimize or reduce debts and possible mergers and acquisitions and other corporate purposes.

 

All above share information last updated at 15 June 2020.

Terms and conditions for the stock options